[1] El-Khoueiry A B, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502.
[2] Zhu AX, Finn RS, Edeline J,et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952.
[3] Assenat E, Pageaux GP, Thezenas S, et al.Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial[J]. Br J Cancer, 2019, 120(9): 896-902.
[4] 原发性肝癌诊疗规范(2019年版)[J].中国临床医学, 2020, 27(01): 140-160.
[5] Kudo M, Finn RS, Qin S, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173.
[6] Kudo M. Subsequent anticancer procedures following first-line lenvatinib(LEN): a post hoc analysis from III REFLECT study in unresectable hepatocellular carcinoma(uHCC)[C/OL]// Kudo M. ASCO-GI, San Francisco, 2020. https://www.asco.org/.
[7] Kudo M. Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma(uHCC) [C/OL]// Kudo M. ASCO-GI, San Francisco, 2020. https://www.asco.org/.
[8] Masafumi I. A Phase Ib Trial of Lenvatinib (LEN) Plus Pembrolizumab (PEMBRO) in Unresectable Hepatocellular Carcinoma (uHCC): Updated Results Ikeda KN524[C/OL]//Masafumi I. AACR, Atlanta, 2019. https://www.aacri.org/.
[9] Josep M Llovet, Masatoshi Kudo, Ann-Lii Cheng, et al. Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study[C/OL]// Josep M Llovet. ASCO, Chicago, 2019. https://www.asco.org/.
[10] Cheng AL, Qin SK, Ikeda M, et al. Atezolizumab + bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma: Phase 3 results from IMbrave150[C/OL]//Cheng AL. ESMO- Asia, Singapore, 2019. https://10times.com/esmo-singapore. |
